Adherence to treatment is of utmost importance in multiple sclerosis (MS) to achieve full benefits from disease-modifying treatments. Thus, we investigated predictors of adherence to interferon β-1a.114 relapsing-remitting MS subjects were recruited and followed-up during 1.536 ± 0.961 years. RebiSmart® (Ares Trading SA, Coinsins, Switzerland), an electronic auto-injector, allows real-time recording of adherence which was retrospectively evaluated, and subjects were categorized accordingly: fully adherent (if no doses were missed), early or late missing (if missing the first dose during the first month of observation or later). The occurrence of clinical relapses and the annualized relapse rate (ARR) were prospectively recorded.Adherence was 95.0 ± 9.0

作者：Marcello, Moccia；Raffaele, Palladino；Cinzia, Russo；Marco, Massarelli；Antonio, Nardone；Maria, Triassi；Alessandra, Lugaresi；Vincenzo, Brescia Morra

来源：Expert opinion on drug delivery 2015 年 12卷 12期